Large RCTs on GLP-1 RAs have also consistently demonstrated that these drugs exert beneficial effects on the risk of adverse cardiovascular outcomes, all-cause mortality and worsening of nephropathy in patients with T2DM [22,23,24]. Here, GLP1R is linked to type 2 diabetes mellitus.